Vibrio rumoiensis

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Vibrio rumoiensis is a Gram-negative, non-spore-forming, facultatively anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 2 gut microbiome compilation studies or metastudies. The DNA G+C content is 43.2%. Vibrio rumoiensis is likely to be transient and not a long-term gut coloniser. (Yumoto1999)



  • This organism has been recovered from the waste stream of a fish processing facility, Japan. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. Likely to be transient and not a long-term gut commensal.
    • QUIRKS
  • Low growth temperatures of 2-34C suggest it is an unlikely gut coloniser.
    • GENERAL CHARACTERISTICS (Yumoto1999);
    Character Response
  • Substrates hydrolysed or digested:
  • chitin; DNA; starch;
  • 🧂
  • Salt tolerance:
  • doesn't tolerate 0% salt; tolerates 6% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 2℃; grows at 34℃;
  • H+
  • Acid from carbohydrates usually produced:
  • L-arabinose; fructose; glucose; mannose; xylose; maltose; mannitol;
  • ⥅
  • Substrates assimilated or utilised:
  • L-arabinose; fructose; gluconate; glucose; glycerol; lactose; citrate; malate;
  • Active enzymes:
  • catalase; oxidase;
    • SPECIAL FEATURES (Yumoto1999);
    Character Response
  • ✗
  • Metabolites not produced:
  • Hâ‚‚S; indole;
  • ✓
  • Methyl red test:
  • active
  • ✗
  • VP test:
  • not active
  • ✓
  • NO3➔NO2:
  • reduced
    • RESPONSE TO ANTIBIOTICS (Yumoto1999);
    Class Active Resistant
  • Miscellaneous antibiotics:
  • vibriostatin A 0 129;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Gammaproteobacteria Order:  Vibrionales Family:  Vibrionaceae Genus:  Vibrio Gram stain:  neg O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  the waste stream of a fish processing facility, Japan
    DNA G+C(%):  43.2
    Low T(℃):  2(+)
    Mid T(℃):  34(+)
    NaCl 0.5-2%:  0(neg)
    NaCl >6%:  6(+)
    		Gelatin:  neg Starch:  + Casein:  neg Alginate:  neg Chitin:  + DNA:  + Tween:  20(+) 40(+) 60(+) 80(+)
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    L-Arabinose:  + Fructose:  + Glucose:  + Mannose:  + Xylose:  + Maltose:  + Mannitol:  +
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    L-Arabinose:  + Fructose:  + Glucose:  + Lactose:  + Melibiose:  neg Raffinose:  neg Gluconate:  + Glycerol:  + Sorbitol:  neg Citrate:  + Malate:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  + Catalase:  + ArgDH:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  neg Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    vibriostat_129:  Sens

    References

    SPECIFIC REFERENCES FOR VIBRIO RUMOIENSIS
  • Yumoto1999 - Characterization of a facultatively psychrophilic bacterium, vibrio rumoiensis sp. nov., that exhibits high catalase activity.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR VIBRIO RUMOIENSIS
  • Li2019b - Disordered intestinal microbes are associated with the activity of Systemic Lupus Erythematosus
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • ...............................
    • Added: October 10, 2022